All In Biotech

Investigational drug · Phase 2

TAK-505

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Malignant Solid Tumors.

Phase 2

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "TAK-505"

First trial start

2026

May 11, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "TAK-505", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Malignant Solid Tumors

Approved drugs for the same conditions: Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "TAK-505" as an intervention, largest first.

All trials
  • TakedaTakeda (TAK)

    NCT07436728 · 151 participants (planned) · Start May 11, 2026 · Primary completion Aug 18, 2030

    Drug: TAK-505 · For: Malignant Solid Tumors

    Sites: Orange, California; San Diego, California; San Francisco, California · 15 sites in all

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Malignant Solid Tumors

  • AdebrelimabSHR-8068, HRS -4642Phase 341 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors

  • SHR-7787Phase 23 trials

    Shanghai Hengrui Pharmaceutical Co., Ltd. · Malignant Solid Tumors, Limited-stage Small-cell Lung Cancer, Advanced Solid Tumors

  • SHR-4849Phase 22 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Malignant Solid Tumors

  • SHR-1681Phase 21 trial

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Malignant Solid Tumors

  • SHR-4298Phase 21 trial

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Malignant Solid Tumors

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Takeda.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.